|Other Names||E3 ubiquitin-protein ligase SMURF1, hSMURF1, 632-, SMAD ubiquitination regulatory factor 1, SMAD-specific E3 ubiquitin-protein ligase 1, SMURF1, KIAA1625|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP2104b was selected from the C-term region of human SMURF1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||E3 ubiquitin-protein ligase that acts as a negative regulator of BMP signaling pathway. Mediates ubiquitination and degradation of SMAD1 and SMAD5, 2 receptor-regulated SMADs specific for the BMP pathway. Promotes ubiquitination and subsequent proteasomal degradation of TRAF family members and RHOA.|
|Cellular Location||Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SMURF1 is an E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. This protein interacts with receptor-regulated SMADs specific for the BMP pathway, SMAD1 and SMAD5, in order to trigger their ubiquitination and degradation and thereby their inactivation.
Tajima, Y., et al., J. Biol. Chem. 278(12):10716-10721 (2003).Suzuki, C., et al., J. Biol. Chem. 277(42):39919-39925 (2002).Ebisawa, T., et al., J. Biol. Chem. 276(16):12477-12480 (2001).Zhu, H., et al., Nature 400(6745):687-693 (1999).Lambris, J., et al., J. Immunol. Methods 27(1):55-59 (1979).
If you have any additional inquiries please email technical services at email@example.com.